CAR T-Cell FDA Approval: Status Update In addition to the approval of Kymriah, Yescarta (axicabtagene ciloleucel or Axi-Cel) was approved on October 18, 2017 for the treatment of adult patients …
CAR T-Cell Therapy HCP Guide – Updates from the FDA Read More
Published September 18, 2017 CAR T-cell therapy is a revolutionary immunotherapy treatment that supercharges a patient’s own blood cells to seek out and destroy cancer cells. Thanks to CAR T-cell …
VIDEO: CAR T-cell Therapy for Pediatric Leukemia: Sam’s Story Read More
September 6, 2017 (HealthDay News) In leukemia/lymphoma, after treatment CD19-targeting chimeric antigen receptor T-cell therapy Outcomes of treatment with third-generation CAR T-cell therapy in CD19-positive B-cell malignancy are associated with …
Immune Status Tied to Outcomes in Third-Gen CAR T-Cell Therapy Read More